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Background: Post-traumatic stress disorder (PTSD) is a severe anxiety disorder that affects a substantial portion of
combat veterans and poses serious consequences to long-term health. Consequently, the identification of
diagnostic and prognostic blood biomarkers for PTSD is of great interest. Previously, we assessed genome-wide
gene expression of seven brain regions and whole blood in a social defeat mouse model subjected to various
stress conditions.
Results: To extract biological insights from these data, we have applied a new computational framework for
identifying gene modules that are activated in common across blood and various brain regions. Our results, in the
form of modular gene networks that highlight spatial and temporal biological functions, provide a systems-level
molecular description of response to social stress. Specifically, the common modules discovered between the brain
and blood emphasizes molecular transporters in the blood-brain barrier, and the associated genes have significant
overlaps with known blood signatures for PTSD, major depression, and bipolar disease. Similarly, the common
modules specific to the brain highlight the components of the social defeat stress response (e.g., fear conditioning
pathways) in each brain sub-region.
Conclusions: Many of the brain-specific genes discovered are consistent with previous independent studies of
PTSD or other mental illnesses. The results from this study further our understanding of the mechanism of stress
response and contribute to a growing list of diagnostic biomarkers for PTSD.Background
Post-traumatic stress disorder (PTSD) is an anxiety dis-
order that is triggered after exposure to traumatic events.
Individuals with PTSD have persistent fear memory and
often feel emotionally numb. If left untreated, PTSD can
be life-threatening, as it is often linked with substance
abuse and severe depression. A study of 289,328 Iraq and
Afghanistan veterans who were first-time users of Vet-
erans Affairs (VA) health care between 2002 and 2008
showed that 22% of veterans were diagnosed with PTSD
and 17% were diagnosed with depression [1]. Given the* Correspondence: doyle@engineering.ucsb.edu
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reproduction in any medium, provided the orpredominance of PTSD and its negative consequences to
long term health, it is very important to identify measur-
able and quantifiable biological parameters, i.e., bio-
markers, which can serve as prognostic and diagnostic
indicators for PTSD. Recent studies have proposed several
candidate brain gene biomarkers that are associated with
PTSD [2,3]. Even though PTSD is an illness of the brain,
taking brain biopsy or spinal fluid is not a viable option
for diagnosis. Instead, blood can be used as a surrogate for
brain tissue for the purpose of identifying biomarkers
[4-8]. Specifically, Rollins et al. recently found over 4,100
brain transcripts co-expressed in the blood of healthy hu-
man subjects [9]. Furthermore, it was shown that the
mRNA levels of certain transcripts in PTSD patients re-
main changed with respect to controls even 16 years after
the traumatic event [8,10]. Thus, blood gene expression
assays are of particular interest for both short-term andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, the identification of predictive blood markers re-
quires the accurate separation of biologically relevant core
markers from unrelated downstream signals. This task is
particularly challenging when using surrogate tissues,
since biological noise from the surrogate is confounded
with noise from the primary tissue. Fortunately, studies
performed with model organisms allow the direct assay of
both surrogate and primary tissues. By characterizing the
molecular changes present in both tissues simultaneously,
we can more effectively filter out spurious signals in the
surrogate.
We recently used repeated exposures of mice to a
trained aggressor mouse as a “social defeat” model for
evaluating PTSD symptoms [11]. This social defeat
model has often been used to induce anxiety,
depression-like and avoidance symptoms, which are the
most prominent psychiatric features of PTSD and com-
mon co-morbidities. Using a “cage-within-cage resident-
intruder” protocol (designed to model unpredictable
threats of daily trauma), we exposed individual subject
male C57BL/6 J mice to single aggressors for six hours
daily for 5 or 10 days, and we placed individual control
subject mice in the same cages but in the absence of any
other mice. After allowing the subject animals to recover
for either 1 or 10 days (5 day exposure) or 1 or 42 days
(10 day exposure), we then collected tissue samples of
blood and seven brain regions of mice under the differ-
ent stress conditions and measured gene expression
levels of these tissues using DNA microarrays. As de-
scribed in [11], the durations of aggressor exposure were
chosen to simulate shorter term (5-day) and longer term
(10-day) stress. The shortest recovery phase duration
(1 day) was chosen to study the immediate effects of
stress. The longer of the two recovery phase durations
for each exposure time were selected based on behav-
ioral tests conducted throughout the study. These tests
demonstrated 5-day exposure defeated mice showed
signs of recovery around 10 days post-exposure, and 10-
day exposure defeated mice showed signs of recovery at
much longer times (up to 42 days post-exposure). Be-
cause PTSD represents a persistent stress response, it is
important to identify differentially expressed genes
(DEGs) active both immediately after the exposure and
after a long recovery period. Thus, in the current work
we focus on genes consistently over-/under-expressed
across all experimental conditions, rather than on DEGs
from individual conditions (we will address the latter in
future work). The seven brain regions analyzed in this
study were chosen due to their known roles in fear
memory formation, emotion regulation, and decision-
making—all processes important to the development
and pathology of PTSD [3]. In particular, the amygdala
regulates fear memory and emotional aspects; thehippocampus is the center for short term memory, and
the prefrontal cortex controls decision-making. In
addition, the ventral striatum is strongly associated with
emotional and motivational aspects of behavior, the stria
terminalis serves as a major output pathway of the
amygdala, and the septal area plays a role in reward and
reinforcement along with the ventral striatum. We note
that a similar protocol has also recently been used to
profile social defeat-induced gene expression changes in
the nucleus accumbens, ventral tegmental area, and
blood plasma [12-14].
The field of systems biology has demonstrated that
complex diseases such as PTSD are not caused by
changes in a single gene or pathway. Rather, changes
occur in a hierarchy of gene modules which collectively
contribute to disruption of essential cellular functions
[15-17]. To characterize this module hierarchy, many re-
searchers have adopted an unsupervised approach
[17-25] that constructs a network based on gene expres-
sion data and identifies functional modules based on
network topology or “guilt-by-association”. However,
these methods usually face the problem of under-
determination, where the number of interactions to be
inferred far exceeds the number of independent mea-
surements [22]. Other studies have adopted a supervised
network identification approach that begins with a list of
“seed” genes and gradually expands the list by adding
interacting genes, ultimately resulting in a compact gene
module network [26-28]. These supervised approaches
have shown good performance for classification tasks,
and we expand upon one of them in this work.
Previous computational and experimental work sug-
gests that functional gene modules are highly conserved
across conditions, tissues, and species [17,29,30]. Direct
comparisons have been made between multiple mouse
tissues [21], between human and mouse brains, and be-
tween human blood and brain tissue [4]. However, mod-
ules inferred separately from different conditions yield
partial overlaps at best, which makes drawing compre-
hensive biological conclusions difficult. Recently, we de-
veloped a new module identification tool entitled
COMBINER (COre Module Biomarker Identification
with Network Exploration) that identifies distinct con-
served expression modules across various conditions.
The fundamental idea behind COMBINER is to infer
candidate modules from data of one condition and valid-
ate the inferred modules in other conditions using su-
pervised classification. Those candidate modules that
perform well in classifying samples from multiple condi-
tions are then defined as “core modules”. There are
three advantages to this approach: (1) The resulting
modules are compact and thus exclude unrelated down-
stream signals; (2) The modules are distinct and well-
defined with respect to which conditions/tissues/species
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discriminative biomarkers co-validated in at least two
experimental conditions. Given these advantages, we
have applied a customized version of COMBINER to
mouse social defeat gene expression data deriving from
seven brain regions along with blood to identify com-
mon expression modules.
In this work, we have attempted to answer two bio-
logical questions: 1. Which expression modules act in com-
mon between blood and brain tissue of the social defeat
mouse model? 2. Which modules act in common between
different brain regions? To do so, we first performed a pair
wise comparison of differential gene expression, biological
pathways, and GO terms between tissues. We then applied
a new version of COMBINER which we modified in two
ways (discussed below). First, we used linear models to
deconvolve time-dependent effects on gene expression
from effects due to social defeat. Second, we developed an
improved consensus feature elimination method to iden-
tify robust modules from data with a relatively small sam-
ple size. Our results, in the form of blood-brain and brain-
brain social defeat core module networks, provide a con-
cise biological description of social defeat and generate
many candidate PTSD biomarkers for future study.Figure 1 Overlap analysis between blood and brain regions. Numbers
on the diagonal, while hyper geometric p-values are listed in the off-diago
We consider the DEPATH overlap between hippocampus and stria termina
supported by a highly significant DEG overlap between the same tissues. (H
medial prefrontal cortex, VS: ventral striatum, SE: septal region and ST: striaResults and discussion
Overlaps of DEGs/DEGOs/DEPaths
First, we identified differentially expressed genes (DEGs)
in each individual tissue across all time points using a
limma moderated t-test [31]. The numbers of significant
DEGs (p ≤ 0.05) for each tissue are listed in blue on the di-
agonal in Figure 1a. We then established the significance
of DEG overlaps by computing a hypergeometric p-value
for each pairwise tissue combination (listed in the off-
diagonal). Hypergeometric p-values ≤ 0.05 are considered
significant (cells highlighted in red in Figure 1a).
Next, we identified differentially expressed Biological
Process GO terms (DEGOs) in each tissue by first ranking
all genes in descending order of limma significance and
then performing Iterative Group Analysis (iGA) [32] for
each GO term with ≤ 100 constituent genes. We com-
puted p-values for each term’s iGA score using a null dis-
tribution obtained via 1000 random permutations of the
original gene order. The numbers of significant DEGOs
(p ≤ 0.05) for each tissue are listed in blue on the diagonal
in Figure 1b. We established the significance of DEGO
overlaps in the same manner as in Figure 1a.
Finally, we identified differentially expressed MSigDB
[33] (www.broadinstitute.org/gsea/msigdb/) canonicalof significant DEGs (a), DEGOs (b), and DEPATHs (c) are listed in blue
nal. P-values≤ 0.05 are considered significant (cells highlighted in red).
lis to be marginally significant (red font), as it has a p-value≤ 0.1 and is
B: hemibrain (hemisphere), AY: amygdala, HS: hippocampus, MPFC:
terminalis).
Table 2 Significantly overlapping DEPATHs between
hippocampus and stria terminalis
Name
Number of
significant genes p-value FDR
SA caspase cascade 6 0.005 0.400
BioCarta IL1R pathway 10 0.010 0.440
KEGG cytosolic DNA sensing pathway 9 0.021 0.499
KEGG graft versus host disease 6 0.029 0.562
KEGG prostate cancer 9 0.030 0.562
BioCarta keratinocyte pathway 9 0.046 0.636
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with the following modification. For each pathway, we
performed iGA separately for all ordered sub-pathways
ranging in size from three to 10 genes (when genes are or-
dered in terms of limma significance). We selected the
highest scoring sub-pathway and established significance
as before by repeating the procedure on 1000 random
gene order permutations. The numbers of significant
DEPATHs and significant DEPATH overlaps are denoted
in the same manner as above.
The overlaps of particular interest include amygdala-
hippocampus (AY-HC) and hippocampus-stria terminalis
(HC-ST), as these two scored significantly in the DEG
comparison and significantly or nearly significantly, re-
spectively, in the DEPATH comparison. These DEPATHs
describe processes such as inflammation, diabetes, apop-
tosis, and immune response. Tables 1 and 2 show the sig-
nificantly overlapping DEPATHs of AY-HC and HC-ST,
respectively. We list the original name of each sub-
pathway along with the following information from the
iGA sub-pathway analysis conducted on the hippocampus
data: number of genes in the highest scoring sub-pathway
(Sig. Genes), sub-pathway permutation p-value, and
Benjamini-Hochberg corrected sub-pathway false discov-
ery rate (FDR). We note that none of these pathways
would have been identified as significant from the hippo-
campus data alone when using a FDR ≤ 0.05 cut-off. We
also note significant overlaps in the blood-septal region
and blood-Hemibrain comparisons, where DEGOs related
to apoptosis and DEPATHs related to insulin/diabetes, re-
spectively, were identified. Additional file 1: Table S1 and
Additional file 2: Table S2 contains detailed lists of these
DEGOs and DEPATHs, respectively.
Core module network
Although the differential expression overlap analysis
provided some biological insight into the pairwise mo-
lecular similarities between mouse tissues during social
defeat, overlap results between DEGs, DEGOs, and
DEPATHs were not always consistent. Overlap analysis
between multiple tissues is more desired, while these
overlaps are very limited due to the high noise-to-signal
ratio of microarray. In addition, it was not obvious how




significant genes p-value FDR
BioCarta cytokine pathway 9 <0.002 <0.220
BioCarta inflam pathway 8 0.002 0.220
KEGG type I diabetes mellitus 7 0.012 0.440
KEGG JAK STAT signaling pathway 10 0.014 0.456
FDR denotes false discovery rate.description of mouse social defeat. Thus, we turned to a
network-level analysis to provide deeper insight. Because
the desired diagnostic biomarkers should be generally
over-expressed in both the stress treatment and recovery
period, we extended the COMBINER method [28] to
accommodate all four conditions, which resulted in
multiple-time-segment data. However, we would expect
an age effect in the control mice. For example, the gene
expression patterns of control mice in the 10-day treat-
ment 1-day recovery and 10-day treatment 42-day recov-
ery groups were significantly different due to mouse age.
Thus, we used the limma software [31] to deconvolve
the undesired effects of differing mouse ages as explana-
tory variables in a linear model, and we subtracted these
variables from the original gene expression values. We
then applied COMBINER to the “time standardized”
data to construct a blood-brain network (common mod-
ules co-expressed in blood and seven brain regions,
Figure 2) and a brain-brain network (common modules
co-expressed in six brain regions, Figure 3).
Blood-brain network
We first investigated the expression modules active in
both blood and multiple brain regions. Starting with the
top 100 candidate modules (when ranked by pathway ac-
tivity absolute t-score—see Methods) inferred from
blood sample data, we identified modules that were also
active in each brain region. To do so, we removed fea-
tures using Consensus Feature Elimination until the
average classification Area Under the ROC Curve (AUC)
evaluated on each brain region exceeded 0.75 (see [28]
for additional details). After repeating this procedure
separately for all brain regions, a total of nine core mod-
ules remained. Figure 2a presents each module’s brain
region-specific expression patterns. We used average
time curves (see Methods) to show the time-specific
expression pattern of the modules as heat maps in
Figure 2a. Figure 2b further shows the expression of the
core modules and the protein-protein interactions (PPIs)
between their gene products. The color of each gene
denotes its expression level in the blood. Blue lines
denote known PPIs within modules, while gray lines
Figure 2 Blood-brain network. (a) nine expression modules resulted from consensus feature elimination; their brain-specific expression
locations are indicated with numbered blue circles. Time-specific blood expression patterns of each module are displayed using average time
curves in the form of expression panels. (b) the blood expression level of each gene in the nine modules is indicated with a colored circle.
Known protein-protein interactions (PPIs) are marked by lines connecting genes—blue lines denote within-module interactions, while gray lines
denote between-module interactions. (c) the putative biological functions of the expression modules are listed (as inferred using the KEGG
annotation). (HB: hemibrain (hemisphere), AY: amygdala, HS: hippocampus, MPFC: medial prefrontal cortex, VS: ventral striatum, SE: septal region
and ST: stria terminalis; 5D-1D/10D: 5 day treatment, 1 day/10 day recovery, 10D-1D/ 6 W: 10 day treatment, 1 day/6 week recovery).
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putative biological functions of the core modules; de-
tailed module information is summarized in Additional
file 3: Table S3. We note that use of COMBINER
resulted in seven discriminative blood biomarker sets
(average 0.81 mean AUC and 0.26 mean error rate)
which have each been validated using data from one of
the brain regions. Table 3 lists the final number of mod-
ules identified from each blood-brain region pair with
the associated mean AUC and mean error rate.
The resulting nine core modules represent biological
functions related to molecular transport, integrin and
tight junction function, retinol metabolism, cell cycle,and mRNA transcription. Although initially inferred
from blood tissue, most of these processes have been
previously implicated in normal and pathological brain
function. For example, tight junctions and ABC efflux
transporters are present in the blood-brain barrier (BBB)
and the blood-cerebrospinal fluid barrier (BCSFB)
[34,35], and SLC transporters encode facilitated trans-
porters and ion-coupled secondary active transporters
such as neurotransmitters. The latter also represent the
major class of transporters used in the delivery of drugs
to the brain [36]. In addition, overexpressed integrin
genes lead to vascular remodeling, which is believed to
be highly correlated with mild Traumatic Brain Injury
Figure 3 (See legend on next page).
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Figure 3 Brain-brain network. (a) application of COMBINER to brain data yields thirty-seven core modules. The tissue- and time-specific
expression patterns of each module are presented in the same manner as before. (b) the expression levels and known PPIs of the core module
genes are displayed. The shape of a gene represents its inference region, and the color denotes its expression level in that region. Blue lines
denote known within-module protein-protein interactions (PPIs), while gray lines denote between-module PPIs. (HB: hemibrain (hemisphere), AY:
amygdala, HS: hippocampus, MPFC: medial prefrontal cortex, VS: ventral striatum, SE: septal region and ST: stria terminalis; 5D-1D/10D: 5 day
treatment, 1 day/10 day recovery, 10D-1D/ 6 W: 10 day treatment, 1 day/6 week recovery).
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are important for the maintenance of the nervous sys-
tem and may play a role in Alzheimer’s disease [38].
The resulting 43 core genes also exhibit ample evidence
for association with brain function and/or PTSD. In par-
ticular, the genes Abca4, Fech, Magoh, Ppp1r12b, and Uros
were previously shown to be differentially expressed in a
human PTSD signature discovered by Segman et al. [8].
Seven of the 43 genes closely resemble genes from a blood
signature for depression (Ahsp, Dhrs9, Map2k2, Slc13a2,
Slc16a1, Slc39a3, U2af1) [39,40], while Hmbs, Pafah1b1,
Sfrs2, and Yes1 were previously identified as bipolar dis-
order blood markers [41]. In addition, Ugt2b5 and Slc6a9
are also present in a blood signature for brain injury [42],
while Dbh, Itgb1, Ltc4s, and Rhoa were reported to be rele-
vant to mTBI [43]. Many of the other genes have been
associated with various mental illnesses and neurodege-
nerative diseases, including Schizophrenia, Alzheimer’s
disease, and sleep disorder. Detailed associations and refer-
ences are listed in Additional file 4: Table S5.
Brain-brain network
In a similar manner as before, we first used COMBINER
to infer the top 100 candidate modules for each brain re-
gion. We then identified common modules for each
remaining brain region separately, removing features
using Consensus Feature Elimination until the average
AUC of the second region exceeded 0.75. Table 4 lists
the final number of modules identified from each brain
region pair, as well as the number of “core” modules and
“core” genes for each brain tissue (i.e. those present in
the majority of pair wise comparisons). In total, 37 core
modules with 177 genes were identified in the brain-
brain network.Table 3 Identified final modules between blood and brain reg
of both tissues
Validation HB AY HC ST M
Inference
Blood 92 20 23 27
Final gene 171 52 51 70
Mean AUC 0.73 0.85 0.79 0.86
Mean error rate 0.24 0.24 0.29 0.22
The mean AUC and error rate were calculated by 500 LDA classifiers with random s
hippocampus, MPFC medial prefrontal cortex, VS ventral striatum, SE septal region aWe list the final number of modules identified from
each brain region pair, as well as the overall numbers of
core modules and core genes for each region. Figure 3a
displays the tissue- and time-specific expression patterns
of each brain-brain core module. Figure 3b shows the
expression levels of the genes in each module, as well as
the known PPIs occurring between genes. Unlike the
blood-brain network, the shape of a gene represents the
brain region in which it was inferred. Table 5 provides
the putative biological functions of the core modules as
inferred, while detailed module information is summa-
rized in Additional file 5: Table S4.
In the brain-brain core module network, Modules 6, 8,
33, and 15 are of particular interest. An active Module 6
(Creb3l2, Prkx, Avp) in the hippocampus indicates a
down regulated PKA-CREB long term potentiation path-
way, which has been shown to impair memory [44]. In
addition, the activity of Module 8 (Prka1b, Hspa1a,
Nfkbia, Jun, Cpt1b) in the septal region shows down
regulation of a heat shock protein (HSPA1A). Such ac-
tivity has previously been found in other PTSD studies
[45]. Module 33 depicts an up regulated dopamine path-
way in the ventral striatum. This activity could potentially
send excessive dopamine to the amygdala and other brain
regions, which has been shown to lead to increased
anxiety [46,47]. Finally, Module 15 implies an active pro-
inflammatory response in the medial prefrontal cortex
(MPFC) that agrees with the study in [48]. Other validated
findings include olfactory impairment in the stria
terminalis (ST) (module 32) [49]; alteration of comple-
ment pathways in the MPFC (module 20) [50] and acti-
vated coagulation function in the ST (module 31) [51].
The above findings highlight that while the putative
biological functions of the brain-brain core modulesions with the associated mean AUC and mean error rate
PFC SE VS Core module Core gene




ampling on both tissues. (HB hemibrain (hemisphere), AY amygdala, HS
nd ST stria terminalis).
Table 4 Numbers of COMBINER modules identified using
data from six brain regions




AY / 17 25 23 0 16 1 4
HC 17 / 7 25 7 18 6 28
ST 22 29 / 23 7 22 9 45
MPFC 22 31 22 / 5 22 9 41
SE 18 26 25 17 / 28 10 53
VS 22 30 13 5 5 / 2 6
(HB Hemibrain (Hemisphere), AY amygdala, HS hippocampus, MPFC medial
prefrontal cortex, VS ventral striatum, SE septal region and ST stria terminalis).
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tical overlap analysis (Tables 1 and 2), the COMBINER
network-based analysis provides a much richer molecu-
lar description of mouse responses to social defeat. With
additional validation in human studies, we expect these
findings to yield robust prognostic and diagnostic bio-
markers for PTSD.
Conclusions
The identification of diagnostic and prognostic blood
biomarkers for PTSD currently is of great interest. In
this work, we have improved the COMBINER method—






NOD like receptor 5
Vasopressin 6




Neuroactive ligand receptor 11
Muscle contraction 12
Systemic lupus erythematosus 13
DNA Repair 14
IRS Related events 15
Post translational protein modification 16
Arachidonic acid 17
ABC Transporters 18
Phosphadylinositol signaling 19sion modules that are activated in common across ex-
perimental conditions—and applied it to blood and brain
data from a mouse social defeat model. The resulting
gene networks highlight stress-related biological pro-
cesses active in both brain and blood and provide a com-
prehensive molecular description of social defeat. In
total, our approach identified seven blood biomarker sets
that have each been validated for classification perform-
ance in one brain sub-region. Some of the genes and
processes discovered are consistent with previous inde-
pendent studies of PTSD or other mental illnesses, while
others represent novel candidate PTSD biomarkers. We
note that the same approach can be readily applied to
other disease models to construct gene networks that
are activated in common across tissues; future work will
focus on this task.
Methods
Blood, organ and tissue collection
Terminal organs, brain regions, and blood samples from
subject and control C57BL/6 mice were collected after
24 hours, or 6 weeks (42 days) post 10-day social stress,
and 24 hours or 1.5 weeks post 5-day social stress.
Brains of C57BL/6 mice were carefully removed from
the skulls, and left or right hemi-brain from each
defeated or control mouse was dissected into different
anatomical and functional regions: Hemibrain (Hemi-
sphere) (HB), amygdala (AY), hippocampus (HS), medials in brain-brain network
Pathway Module
Complement and coagulation 20
Neurotrophin signaling 21
Regulation of beta cells 22
Transmembrane transport 23
Myogenesis 24






Complement and Coagulation 31
Olfactory transductoino 32
Class A1 rhodopsin like receptors 33
Host interaction of HIV factors 34
Peptide ligand biding receptors 35
Calcium signaling 36
Downstream TCR signaling 37
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region (SE) and stria terminalis (ST). The number of
defeated and control mice in different regions and con-
ditions are summarized in Table 6.
RNA isolation and quality assessment
Total RNA was isolated according to the Trizol® method
(Invitrogen Inc., Grand Island, NY) from homogenized
whole blood and brain regions. RNA from blood was
isolated using the PreAnalytiX PAXgene® blood RNA kit
(Qiagen Inc., Valencia, CA). We collected the seven
organ tissues from 5-6 control and defeat mice, respect-
ively. We evaluated RNA integrity using the Agilent
Bioanalyzer and excluded samples of low quality, which
appears to either have low total RNA, or low ribosomal
RNA (rRNA) mass ratio between 28S and 18S rRNA
and high amount of non-ribosomal RNAs in the
electropherograms.
Microarray hybridization
Microarray assays were performed using Agilent’s gen-
ome wide mouse expression array (GE 4x44K v2 two
color microarray) slides and kits (Agilent Technologies
Inc., Santa Clara, CA) following the manufacturer’s
protocol. To minimize batch effects, each sample was
hybridized with a universal common reference that was
used for all experiments. Hybridized microarray slides
were scanned using Agilent Technologies Scanner
G2505C US09493743.
Microarray data processing
Genespring with feature extraction 10.x (Agilent, CA) was
used to process all two-color chips. Log2 transformation,
Lowess normalization, and quantile normalization were
applied to normalize within and between microarrays. For
the latter, we applied quantile normalization separately on
data from each tissue. Outlier spots were converted toTable 6 Defeated and control mice (in the form of
(number of defeated) / (number of control)) in different
regions and conditions
Condition
5D-1D 5D-10D 10D-1D 10D42D
Tissue
Blood (5) / (5) (5) / (5) (5) / (4) (5) / (5)
HB (Hemibrain) 5) / (5) (5) / (5) (5) / (5) (5) / (5)
AY (Amygdala) (2) / (3) (4) / (5) (4) / (3) (4) / (3)
HC (Hippocampus) (4) / (3) (6) / (4) (5) / (6) (5) / (5)
MPFC (Medial Prefrontal Cortex) (5) / (4) (5) / (5) (4) / (3) (4) / (4)
SE (Septal Region) (2) / (3) (3) / (2) (3) / (3) (3) / (3)
ST (Stria Terminalis) (5) / (5) (5) / (5) (4) / (4) (5) / (4)
VS (Ventral Striatum) (5) / (5) (5) / (5) (4) / (4) (4) / (5)
(5D-1D/10D: 5 day treatment, 1 day/10 day recovery, 10D - 1D/ 6 W: 10 day
treatment, 1 day/6 week recovery).missing values. If more than half of the expression values
of a probe were missing, we removed the probe from con-
sideration. We then imputed missing values using the k-
nearest neighbor imputation method. To avoid incurring a
bias in favor of genes represented by a greater number of
probes, we aggregated multiple probes from the same
Entrez Gene together by computing the mean of the “sib-
ling” probes. We have deposited all microarray data for




We used a linear model-based approach to deconvolve
the experimental time effects from the social defeat ex-
pression data. Assuming log-additive effects, our method
estimates the contributions of each of the four experi-
mental time points and subtracts them away from the
remaining effect of social defeat. The linear model we
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where Di and Ci i = 1, …, 4 denote log2 gene expression
values of defeated and control mice in condition i, αdefeat
denotes the overall effect of social defeat and β1, …, β4
are the undesired time effects. In practice, we solve the
above over determined system for each gene separately
using least squares (implemented in the limma package),
carrying forward only the gene-specific defeat effect for
subsequent analyses.
Differential expression analysis
As described above in Section 2, we used the R/Biocon-
ductor limma package and iterative Group Analysis
(iGA) method for differentially expressed gene and GO
term/pathway identification, respectively.
COMBINER
As shown in Figure 4, the COMBINER method first
infers the statistically discriminative modules from an
inference dataset, then validates them in various valid-
ation sets using consensus feature elimination. If a vali-
dated final module is co-expressed in at least half of the
validation sets, then it is defined as a core module.
Finally, we project these core modules onto known PPI
Figure 4 Schematic overview of COMBINER. COMBINER first infers candidate modules as activity vectors from each pathway in an inference
dataset. It then validates these modules in validation datasets by regenerating activity vectors and performing supervised classification. Finally, the
modules present in at least half of the validation sets are considered to be core modules. The resulting core module markers are then projected
onto a known protein-protein interaction network. We generated 250 groups of 500 classifiers in parallel using LDA with recursive feature
elimination. Both the classifier AUC and weight vectors were computed, and each feature was then ranked by its average normalized weight. The
most consistently low-ranking feature was then removed recursively until the average AUC threshold was achieved. At this point, the remaining
markers were considered to comprise the final modules.
Yang et al. BMC Systems Biology 2013, 7:80 Page 10 of 12
http://www.biomedcentral.com/1752-0509/7/80networks. To remove features, we generated 250 groups
of 500 classifiers in parallel and applied Linear Discrimin-
ant Analysis (LDA) with recursive feature elimination [52]
to each to compute AUCs as well as weight vectors. Each
feature was then ranked by its average normalized weight.
The most consistently low-ranking feature was then re-
moved recursively until the average AUC threshold of 0.75
was achieved. At this point, the remaining features were
considered to comprise the final modules.
In our previous work [28], we applied both the
Condition Responsive Genes (CORG) [53] and Core
Module Inference (CMI) [28] methods to infer can-
didate modules and express them as pathway activ-
ities (PAs). In the greedy search process, CORG
picks up either up- or down-regulated genes, while
CMI identifies genes of both directions together.
However, because of the multiple-time-point nature
of the social defeat data, the application of the CMI
method is not straightforward. Thus, in this work we
used only the CORG method with the procedure de-
scribed as follows. For a given pathway, we first rank
the standardized gene expressions by their limma
moderated t-score. If up-regulated genes are domin-
ant, we rank the t-score in descending order; other-
wise, ascending order is chosen. Next, we aggregate





if the expression of this aggregate yields a larger ab-
solute t-score than the first gene, this combination is
retained as a module with the combined expression
becoming the PA. Otherwise, the procedure further




, and soon, until the module-size limit, 25 genes, is reached.
Finally, we ranked all modules using the absolute
value of the pathway activity t-score.
We faced two major challenges when modifying our
COMBINER method. First, the multiple-time-point na-
ture of the data initially decreased the binary classifi-
cation performance of the static LDA classifier [52].
Second, the small data sample size leads to a large vari-
ability of feature ranks after recursive feature elimin-
ation. To cope with the first challenge, we used a linear
model to deconvolve the time effects from the original
expression values. We solved the second problem by im-
proving our method for consensus feature elimination.
We generated 250 groups of 500 classifiers in parallel,
then removed the bottom feature using the voting
principle. In general, using additional groups of classi-
fiers will further improve the reproducibility of the final
modules. In our experience 250 groups were sufficient
to yield a reproducible result (results not shown). Finally,
we used a fixed average AUC threshold to determine the
final modules instead of the max average AUC threshold
described in [28]. This was required since the inference
and validation sets can be very dissimilar, which leads to
low values of the max average AUC.
We obtained pathway information from the MSigDB
v3.0 Canonical Pathways subset [54]. To decrease redun-
dancy, we applied pathway filtering to remove bulky path-
ways. This resulted in a pathway dataset containing 791
pathways with 5,633 genes assayed in all regions. The
protein-protein interaction information was obtained from
String v9.0 [55].
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Let yij be the relative expression level of gene i at the
sampling time j. The time-point expression patterns
were modelled as follows,
yij ¼ μi tj
 þ εij ð2Þ
where μi tj
  ¼ log2 xD tj
 
=xC tj
    is the population
average time curve for gene i evaluated at time tj and




are average expressions of disease and control
mice respectively for gene i at time tj.
Software
COMBINER was implemented in Matlab R2010a with Bio-
informatics toolbox v3.5 (Math Works Inc., Natick, MA),
statconn (http://www.statconn.com/), LinkR (http://www.
mathworks.com/matlabcentral/fileexchange/5051), and R
[56]. The source code can be found in Additional files 6
and 7.
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